IVIg in TEN: Time to re-evaluate the efficacy of intravenous immunoglobulin in the management of toxic epidermal necrolysis

British Journal of Dermatology

Volumn 167, Issue 2, 2012, Pages 230-231

  Walsh, S ^a   Creamer, D ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

DRUG EFFICACY; HUMAN; NOTE; PATIENT CARE; PRIORITY JOURNAL; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

EPIDERMAL NECROLYSIS, TOXIC; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS;

EID: 84864398623     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.11032.x     Document Type: Note

References (3)

1. Mockenhaupt M, Norgauer J,. Cutaneous adverse drug reactions. Stevens-Johnson syndrome and toxic epidermal necrolysis. J World Allergy Org 2002; 14: 143-150.
2. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490-493.
3. Huang Y-C, Li Y-C, Chen T-J,. The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis. Br J Dermatol 2012; 167: 424-32.